Marker Therapeutics Inc (MRKR)

[Phantom Lord]

As expected IR's response was limited to information that has already been released. I inquired about all trials and responses I received are below:

First, the latest information on all trials can be found by reviewing the latest conference call (HERE) & the latest 10Q (HERE).

*All NCT numbers below are links to the trial page at clinicaltrials.gov

TPIV 200 for ovarian (NCT02978222): "Continuing to enroll patients as efficiently as possible and we remain on track to conduct a blinded interim analysis in 2019." This is the trial that is supposed to have interim results Q1 or Q2 next year so we are still on track.

TPIV 200 for TNBC (NCT02593227): "The data that we have is when we released the TPIV200 findings back in March." The whitepaper can be found HERE & the publication to AACR Clinical Cancer Research can be found HERE.

Combination trial of TPIV 200 & Durvalumab for ovarian (NCT02764333): "Enrollment in this single arm study was suspended as required by the final two stage design, while the first 27 patients were currently enrolled completed their treatment, and the planned interim analysis is conducted. Based on discussion with the study’s clinical investigators the data are still being analyzed and we anticipate reporting results as soon as they are released by the MSKCC." This should be the next data we see. I'm hoping sometime before year's end. If positive this could provide a good boost and keep SP propped up into early next year when data from the Tapimmune sponsored trial of TPIV 200 in ovarian is released.

TPIV 200 for TNBC funded by DOD w/ Mayo Clinic (NCT03012100): "Since we are not sponsors of this trial, you will need to reach out to the Mayo Clinic [with any questions]." I have done so and will post any response I receive.

TPIV 100/110: Mayo has already secured a grant funding from DoD to launch Phase 1B/2A clinical study in women with ductal carcinoma in situ or DCIS breast cancer. The DoD grant may also enable us to expand the types of cancers targeted by our HER2neu vaccine. While the timing of this study is driven by Mayo Clinic we look forward to providing an update as soon as patient enrollment begins. From the Q4 conference call, "the Department of Defense expressed interest in fully funding yet another Phase 2 clinical study to evaluate our five peptide HER2 vaccine, TPIV110, in combination with Herceptin in HER2 new positive breast cancer patients." I would hope to hear something about this new fully funded trial before year's end as well but no timeline has been given thus far.

Info on the Marker therapies HERE & HERE.

I have a couple of outstanding emails and as soon as, and if, I get responses I will post them here.